Hospital initiative fails to pass city commission; needs more signatures
The Clergy Community Coalition now has until Aug. 11 to collect 1,250 valid signatures after already collecting thousands for the hospital initiative.
This comes after Wednesday morning's Dayton City Commission meeting, where their petition to have the initiative appear on November's ballot failed to pass.
One city commissioner, who is also a member of the coalition, says she is upset with this outcome.
'I am disappointed,' said Shenise Turner-Sloss, city commissioner. 'I commitment in doing so and to allow the people to to make the decision to to vote as to whether they will like to support a public hospital. '
Both Turner-Sloss and Mayor Jeffrey Mims Jr. voted in favor of putting the hospital initiative on the ballot. This would have allowed voters to decide if a public hospital is something the city of Dayton should pursue and fund.
'If you have been here for years and decades like myself, you're seeing this city suffer more than other cities around us, and other communities around us, because of the wealth factor,' said Mayor Mims.
Commissioner Darryl Fairchild abstained his vote, and commissioners Chris Shaw and Matt Joseph both voted against the ballot initiative, saying while they are not opposed to a hospital, this initiative lacks proper planning and would not be a good idea for Dayton residents.
'It's unfair for Dayton residents to have to pay for a hospital if it even were able to come to fruition,' said Chris Shaw, city commissioner. 'And if the city of Dayton had to fill the gap, we would have to cut fire and police, public works.'
Commissioners say health care is a priority but the proposal needs to better align with the city's current capabilities.
'And I want to make sure that folks realize that, I acknowledge, as my colleagues all do, that we need help with health care. There's no doubt about it, it's a countrywide epidemic right now,' said Joseph. 'And if there was a reasonable proposal, I'd be glad to work on it.'
Without three 'yes' votes, the hospital proposal cannot go on the November ballot — unless the Community Clergy Coalition collects 1,250 additional signatures in 20 days.
'We got a lot of signatures so far. So I do think that the people of Dayton will do that,' said Sue Sutton, coalition member. 'I just want the people of Dayton to be able to vote on this.'
2 NEWS will continue to follow this story.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Tim Scannell, Former Stryker President & COO, Named Chair of Longeviti Neuro Solutions Amid $10M Capital Infusion From Soleus Capital
Appointment to Chair of the Board and Additional Growth Funding Accelerate Longeviti's Mission in Developing Platform Solutions for Complex Neurological Disorders BALTIMORE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Longeviti Neuro Solutions, a neurotechnology company with a focus on innovative platform solutions for complex brain disorders, today announces the appointment of Tim Scannell, former President & COO of Stryker Corporation, as Chair of its Board of Directors. The company also reveals a $10 million strategic capital partnership with Soleus Capital to accelerate hiring, product development, and medical education efforts in the United States and abroad. Scannell brings a wealth of experience in the medical device market having served in leadership positions with Stryker Corporation for over thirty years. He advanced from sales and marketing to executive leadership roles highlighted by ten years as Group President of MedSurg & Neurotechnology and three years as President and COO of Stryker. He was responsible for assisting in the selection and development of the strategies and talent that delivered over the last three decades and continues to deliver outstanding results today. Scannell is currently scaling MedTech businesses with his involvement as board representative and chair for multiple public and private companies, with the majority offering interaction with neurosciences and neurosurgeons. In his role as Chair, he will assist with formulating strategic plans and providing oversight while serving as a sounding board for management. Longeviti established a strategic capital partnership with Soleus Capital, a healthcare investment firm based in Greenwich, CT. The firm, which invests in the innovative areas of life sciences including medical technology, biotechnology, diagnostics, and life science tools, has committed $10 million in structured financing to fund key strategic priorities for Longeviti. With this capital, Longeviti is poised to accelerate talent acquisition needs, continued development of its groundbreaking neurotechnology platforms, expand its market presence, and continue delivering life-changing innovations that enhance patient care. 'Tim's appointment as Chair of the Board brings world-class leadership and unmatched insight from decades of success in building, and leading, high-performing MedTech companies. His experience will be instrumental as we sharpen our strategy and deepen our impact in neurotechnology. Coupled with the $10 million capital infusion from Soleus Capital, Longeviti now has the momentum to grow our team, advance critical research, and accelerate the development and delivery of life-changing solutions for patients with complex brain disorders,' shared Jesse Christopher, Co-Founder and CEO, Longeviti Neuro Solutions. 'I easily said 'yes' to joining the Board of Directors for Longeviti, mainly because of the talent. I've known several of Longeviti's leaders for years, and admire their tenacity, persistence, and goals to make an instrumental difference in the neuro industry. Longeviti's technology is revolutionary and will support the advancement of patient care in neurosciences, creating a value for the industry, our shareholders, and employees,' said Tim Scannell, Chair, Board of Directors, Longeviti Neuro Solutions and former President and COO, Stryker. 'I'm honored to share my experiences and opinions to support the success of Longeviti.' 'We were introduced to Longeviti by a respected key opinion leader who had firsthand experience using their innovative products in clinical practice. We were deeply impressed by the company's mission and strong operating results,' shared Ben Lund, Partner, Soleus Capital. 'It was clear to us that with the right capital support, Longeviti could scale its team, reach more clinicians and patients, and amplify its impact on those living with complex brain disorders. We are proud to be part of that growth.' About Longeviti Neuro Solutions ( Longeviti Neuro Solutions is a leading innovator in functional neurotechnology, dedicated to developing advanced solutions that improve the lives of patients with neurological conditions during and after surgery, while also returning them to anatomical normalcy. The Baltimore-based company has full manufacturing, packaging, designing, and sterilizing capabilities in-house with multiple FDA clearances, successful FDA audits, and ISO 13485 Certifications. Longeviti has 50 worldwide patents to date. Longeviti's mission is to develop innovative platform solutions for complex brain surgery. Its products are currently approved for use in over 120 hospitals across the globe. To date, Longeviti neurosurgical implants have helped over 4,000 patients. About Soleus Capital ( Soleus Capital is a healthcare investment firm based in Greenwich, CT. Founded in 2018, the company currently has ~$2B in assets under management. Soleus partners with companies across three strategies – public equity, private equity and structured credit – and across each of the life sciences subsectors – biotechnology, medical technology, life science tools and diagnostics. Contact: Nicole Halsey/Natalie Van Buskirk Polished Nichols PR & Marketing nicole@ natalie@ 410.952.2122/443.956.4765 A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
6 minutes ago
- CBS News
Americans get 55% of their calories from ultra-processed foods, CDC report says
Americans on average get more than half of their calories from ultra-processed foods, according to a Centers for Disease Control and Prevention report released Thursday. The report says the average percentage of total calories consumed from ultra-processed foods among those aged 1 and older was 55% from August 2021 to August 2023. Young people, aged 1 to 18 consumed even higher amounts at 61.9%, compared to adults aged 19 and older at 53%. No significant differences were found between males and females, but low-income adults consumed more ultra-processed foods than those with higher incomes. The report described ultra-processed foods as those that tend to be energy-dense, low in fiber and contain little or no whole foods, while also being high in salt, sweeteners and unhealthy fats. Some of the top sources of calories from ultra-processed foods among youth and adults included: For young people, pizza also ranked among the ultra-processed food sources. And for adults, breads, rolls and tortillas made the list. The report comes as Health and Human Services Secretary Robert F. Kennedy Jr. has targeted ultra-processed foods as part of his "MAHA," or "Make America Healthy Again," agenda. Previous research has shown ultra-processed food is associated with a higher risk of cardiovascular disease and all-cause mortality. Research published in The BMJ journal last year found higher exposure to ultra-processed food is associated with 32 damaging health outcomes, including higher risk for cancer, major heart and lung conditions, gastrointestinal issues, obesity, type 2 diabetes, sleep issues, mental health disorders and early death. Other studies have also pointed to the addictive quality of many processed foods. An CBS Reports' investigation on how ultra-processed foods have become so pervasive in the American diet. "Most dietary guidelines, including the Dietary Guidelines for Americans, 2020-2025, recommend eating a variety of whole foods and limiting intake of foods with added sugars," the report states.
Forbes
6 minutes ago
- Forbes
Here's Why Eli Lilly Shares Are Plummeting
Shares of Eli Lilly plummeted 14% on Thursday, pacing what would be the stock's largest loss in decades after the pharmaceutical giant unveiled data for its obesity treatment pill that fell behind Wall Street's expectations. Shares of rival Novo Nordisk rose as both companies develop weight loss pills. NurPhoto via Getty Images Eli Lilly's shares dropped more than 14% to around $639 as of about 2:25 p.m. EDT, marking what would be the company's steepest single-day loss since a 29% decline on Aug. 8, 2000. Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or overweight patients without diabetes lose just over 12% of their body weight in a late-stage trial, behind analyst expectations of 15%, according to FactSet. The highest dosage of Eli Lilly's experimental pill helped more than 59% of patients lose at least 10% of their body weight, while nearly 40% of patients lost at least 15%, and the company said orforglipron helped lessen cardiovascular risks. The findings trailed late-stage trial data from Novo Nordisk, which reported average weight loss of 15% among patients who used an oral version of its Wegovy treatment earlier this year. Eli Lilly CEO David Ricks told CNBC the company was 'not disappointed with these results,' which he noted were 'right on thesis for us' despite falling 'one or two points below what [Wall Street] had.' Orforglipron's average weight loss was 'in the range' of what consumers would want to achieve, Ricks said. Surprising Fact Earlier testing of orforglipron in adults with Type 2 diabetes impressed investors in April, after Eli Lilly reported the highest dose of orforglipron helped patients lose nearly 8% of their body weight, or roughly 16 pounds on average, over a 40-week trial. That data matched Wall Street's projections, and Eli Lilly said trial data indicated its pill helped patients with Type 2 diabetes lower their blood sugar and had safety similar to weight-loss injections already on the market. Eli Lilly's shares surged more than 14% at the time, one of the company's largest single-day gains in the last five years. Shares of Novo Nordisk rose more than 7% by Thursday afternoon in the wake of Eli Lilly's worse-than-expected trial report. Key Background Several pharmaceutical firms, including Eli Lilly, Pfizer and Novo Nordisk, have competed to develop a weight-loss pill following the commercial success of Novo's Ozempic and Wegovy in recent years. Some health experts have argued an oral weight-loss medication would be cheaper to produce and greatly expand the market to more consumers compared to injections, which are the only forms of the drugs currently available. Eli Lilly indicated it would file for regulatory approval of orforglipron by the end of the year, while Novo Nordisk's treatment is currently under regulatory review, with a decision by the Food and Drug Administration reportedly expected in late 2025. Testing of Pfizer's twice-daily danuglipron was abandoned by the company after trial data suggested the drug could adversely affect the liver. Roche and Viking Therapeutics are similarly developing oral weight-loss drugs and reported average weight loss of 6.1% and 8.2% in early- and mid-stage trials, respectively. Further Reading Forbes Novo Nordisk Shares Plunge 21% Toward Worst Day In 40 Years—As Ozempic Sales Expected To Slow By Ty Roush
